XENAZINE

This brand name is authorized in Estonia, France, Israel, Lithuania, Netherlands, United Kingdom, United States

Active ingredients

The drug XENAZINE contains one active pharmaceutical ingredient (API):

1 Tetrabenazine UNII Z9O08YRN8O - TETRABENAZINE

Tetrabenazine is a synthetic derivative of benzylquinolizine that causes depletion of dopamine and other monoamines in the central nervous system. The precise mechanism by which tetrabenazine exerts its effects is unknown, but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Neurotransmitter depletion by a single dose of tetrabenazine is reversible and lasts only a few hours. Read about Tetrabenazine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
XENAZINE Tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N07XX06	Tetrabenazine	N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs
Discover more medicines within N07XX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1595998
Country: FR	Base de données publique des médicaments	Identifier(s): 62463044
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 23232
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4873
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1067976
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 50725
Country: US	FDA, National Drug Code	Identifier(s): 67386-421, 67386-422